

Miguel Angel Canales Albendea

List of Publications by Citations

Source:

<https://exaly.com/author-pdf/5530353/miguel-angel-canales-albendea-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

102
papers

1,606
citations

21
h-index

39
g-index

115
ext. papers

1,933
ext. citations

3.2
avg, IF

3.73
L-index

#	Paper	IF	Citations
102	R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. <i>Haematologica</i> , 2008 , 93, 1829-36	6.6	139
101	Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 172-83	4.7	119
100	Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2395-2404	2.2	100
99	Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. <i>British Journal of Haematology</i> , 2007 , 139, 70-80	4.5	99
98	Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 133	22.4	84
97	Nutritional recommendations in hematopoietic stem cell transplantation. <i>Nutrition</i> , 2008 , 24, 769-75	4.8	82
96	Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. <i>British Journal of Haematology</i> , 2001 , 113, 161-71	4.5	71
95	Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. <i>Cancer</i> , 2009 , 115, 5210-7	6.4	68
94	Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?. <i>American Journal of Hematology</i> , 2008 , 83, 673-5	7.1	67
93	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1530-1542	21.7	59
92	Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. <i>European Heart Journal</i> , 2020 , 41, 1720-1729	9.5	57
91	First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2014 , 1, e104-11	14.6	55
90	Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). <i>Annals of Oncology</i> , 2019 , 30, 612-620	10.3	47
89	Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. <i>Blood</i> , 2017 , 130, 1772-1774	2.2	44
88	A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. <i>Blood</i> , 2010 , 116, e12-7	2.2	39
87	Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: Case report and review of the literature. <i>American Journal of Hematology</i> , 2002 , 69, 127-31	7.1	33
86	A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. <i>Haematologica</i> , 2018 , 103, 1351-1358	6.6	32

85	MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013 , 162, 336-47	4.5	32
84	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , 2014 , 99, 505-10	6.6	26
83	Predictive value of interim 18 F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogeneously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment. <i>Nuclear Medicine Communications</i> , 2013 , 34, 946-52	1.6	25
82	Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. <i>PLoS ONE</i> , 2009 , 4, e8173	3.7	23
81	First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GEL/TAMO group. <i>Haematologica</i> , 2012 , 97, 1512-70	6.6	21
80	Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GEL/TAMO). <i>Blood</i> , 2015 , 126, 582-582	2.2	21
79	Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. <i>Annals of Hematology</i> , 2013 , 92, 1151-79	3	18
78	Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. <i>British Journal of Haematology</i> , 2016 , 173, 245-52	4.5	16
77	Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2011 , 52 Suppl 3, 1-14	1.9	15
76	Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 37-38	2.2	15
75	Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. <i>Leukemia and Lymphoma</i> , 2012 , 53, 812-9	1.9	13
74	Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). <i>Blood</i> , 2015 , 126, 582-582	2.2	13
73	Fecal calprotectin in allogeneic stem cell transplantation for the diagnosis of acute intestinal graft versus host disease. <i>Bone Marrow Transplantation</i> , 2012 , 47, 1241-2	4.4	12
72	A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group. <i>American Journal of Hematology</i> , 2018 , 93, 867-873	7.1	11
71	Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. <i>British Journal of Haematology</i> , 2020 , 191, 386-389	4.5	11
70	Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8506-8506	2.2	9
69	Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). <i>Leukemia and Lymphoma</i> , 2011 , 52, 409-16	1.9	8
68	Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain. <i>Medicina Clínica</i> , 2008 , 131, 441-6	1	8

67	No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19. <i>Transfusion and Apheresis Science</i> , 2020 , 59, 102921	2.4	8
66	Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. <i>Annals of Hematology</i> , 2016 , 95, 893-9	3	8
65	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , 2014 , 99, e126	6.6	7
64	Granulocytic sarcoma (chloroma) of the lung. <i>British Journal of Haematology</i> , 2003 , 120, 176	4.5	7
63	Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-200801). <i>Blood</i> , 2012 , 120, 3691-3691	2.2	7
62	Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1283-9	1.9	5
61	Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. <i>British Journal of Haematology</i> , 2019 , 184, 797-807	4.5	5
60	Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. <i>Acta Haematologica</i> , 2016 , 136, 76-84	2.7	4
59	Schnitzler syndrome. <i>Reumatología Clínica</i> , 2013 , 9, 384	0.9	4
58	Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab. <i>Leukemia Research</i> , 2008 , 32, 199-200	2.7	4
57	Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial. <i>Cancer Medicine</i> , 2019 , 8, 6955-6966	4.8	3
56	Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma. <i>Leukemia Research</i> , 2011 , 35, 431-7	2.7	3
55	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203). <i>Blood</i> , 2020 , 136, 36-37	2.2	3
54	Induction with Fludarabine, Cyclophosphamide and Rituximab Followed by Maintenance with Rituximab: Results of a Prospective Study in 75 Patients (LNHF-03).. <i>Blood</i> , 2006 , 108, 2762-2762	2.2	3
53	Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 111	22.4	3
52	Interim and End-of-Treatment 18F-FDG-PET Evaluation of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment: An Open-Label Clinical Trial in Spain.. <i>Blood</i> , 2009 , 114, 3692-3692	2.2	2
51	Predictive Value for Event-Free Survival of Interim 18F-FDG-PET In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim as First-Line Treatment: An Open-Label Clinical Trial In Spain.. <i>Blood</i> , 2010 , 116, 2793-2793	2.2	2
50	Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too. <i>British Journal of Haematology</i> , 2006 , 134, 645-6	4.5	1

49	Induction with Fludarabine, Cyclophosphamide and Rituximab as Front-Line Therapy Against Follicular Lymphoma: Results from a Cooperative Spanish Trial. <i>Blood</i> , 2007 , 110, 1286-1286	2.2	1
48	Feasibility and Toxicity After Induction Treatment with Rituximab-HCVAD and Metotrexate/Citarabine, Followed by Consolidation with Y-90 Ibritumomab Tiuxetan (Phase II GELTAMO-04-02 study).. <i>Blood</i> , 2009 , 114, 1703-1703	2.2	1
47	Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial. <i>Blood</i> , 2012 , 120, 1639-1639	2.2	1
46	Autologous Stem Cell Transplantation with Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial. <i>Blood</i> , 2012 , 120, 1978-1978	2.2	1
45	Procoagulant Status In Patients With Immune Thrombocytopenia. <i>Blood</i> , 2013 , 122, 3528-3528	2.2	1
44	Thromboelastometry Shows a Prothrombotic State in Systemic Lupus Erythematosus Related to Diminished Fibrinolysis and Microparticle-Derived Tissue Factor. <i>Blood</i> , 2015 , 126, 2317-2317	2.2	1
43	Bayesian Estimation of Pharmacokinetic Parameters in Children and Adolescents with Severe Hemophilia: A Single Center Experience. <i>Blood</i> , 2015 , 126, 3534-3534	2.2	1
42	Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo. <i>Blood</i> , 2016 , 128, 4201-4201	2.2	1
41	Evaluation of Endothelial Damage in Sinusoidal Obstructive Syndrome. <i>Blood</i> , 2016 , 128, 5802-5802	2.2	1
40	Early Detection of Chemotherapy- Induced Cardiotoxicity in Hematological Patients: A Prospective Study. <i>Blood</i> , 2016 , 128, 5988-5988	2.2	1
39	Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203). <i>Blood</i> , 2021 , 138, 813-813	2.2	1
38	Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study. <i>Blood</i> , 2021 , 138, 3573-3573	2.2	1
37	Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2021 , 17, 1295-1310	3.6	1
36	A 60-Year-Old Male Smoker With Chronic Obstructive Pulmonary Disease and Hypereosinophilia. <i>Archivos De Bronconeumologia</i> , 2018 ,	0.7	1
35	A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL). <i>Blood</i> , 2021 , 138, 1420-1420	2.2	0
34	Evaluaci3n del impacto de cartas de condolencia en familiares en duelo. <i>Medicina Paliativa</i> , 2014 , 21, 98-104	1.5	
33	A Long-term Remission of a Recurrent Acute Lymphoblastic Leukaemia with Donor Leukocyte Infusions after Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Hematology</i> , 1997 , 2, 395-8	2.2	
32	Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma. <i>Blood</i> , 2021 , 138, 1345-1345	2.2	

31	Potential Utility of Circulating Tumor DNA Monitoring in Primary Mediastinal B-Cell Lymphoma Treated with R-DA-EPOCH. <i>Blood</i> , 2021 , 138, 4491-4491	2.2
30	Evaluation of Platelet Function Defects in Patients with Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 1021-1021	2.2
29	Laboratory Characterization of Unclassified Bleeding Disorders By Non-Conventional Tests. <i>Blood</i> , 2021 , 138, 4235-4235	2.2
28	Glycomic Characterization of Platelets from Patients with Immune Thrombocytopenia. <i>Blood</i> , 2021 , 138, 3158-3158	2.2
27	Evaluation of Global Coagulation Tests for Monitoring Bleeding Phenotypes and Response to Treatments in FVII Deficiency. <i>Blood</i> , 2021 , 138, 1046-1046	2.2
26	Rituximab Combined with Intravenous or Oral Fludarabine for Previously Untreated Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients.. <i>Blood</i> , 2007 , 110, 4450-4450	2.2
25	Features of Microparticle-Associated Procoagulant Activity in Patients with Thrombocytopenias of Immune and Central Origin. <i>Blood</i> , 2014 , 124, 1462-1462	2.2
24	Case-Control Pilot Study of the Immune Modulating Effect of FEIBA [®] on Patients with Haemophilia a and Inhibitors. <i>Blood</i> , 2015 , 126, 4688-4688	2.2
23	Haemostasis Impairment in Patients with Myelodysplastic Syndromes with Normal Platelet Counts. <i>Blood</i> , 2015 , 126, 5225-5225	2.2
22	Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study. <i>Blood</i> , 2015 , 126, 1508-1508	2.2
21	Platelet Features from ITP Patients Responders to Different Therapeutic Treatments. <i>Blood</i> , 2015 , 126, 4648-4648	2.2
20	Phase 2 Randomized Trial Comparing 6 Cycles of Standard RCHOP Chemotherapy Vs 6 Cycles of Brcap (bortezomib, rituximab, cyclophosphamide, adriamidine and prednisone) As First Line Treatment in Young Patients with Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Interim Analysis. <i>Blood</i> , 2015 , 126, 1511-1511	2.2
19	Procoagulant Profile in Patients with Immune Thrombocytopaenia. <i>Blood</i> , 2015 , 126, 1062-1062	2.2
18	Response-Adapted Treatment with Rituximab/Bendamustine/Mitoxantrone/Dexamethasone and Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. RBMDGELTAMO08 Trial. <i>Blood</i> , 2016 , 128, 1788-1788	2.2
17	Procoagulant Profile of Platelets from Immune Thrombocytopenia Patients. <i>Blood</i> , 2016 , 128, 1370-1370	2.2
16	Haemostasis in Immune Trombocytopenia Patients Responders to Agonists of Thrombopoietin Receptor. <i>Blood</i> , 2016 , 128, 3743-3743	2.2
15	First-Line Treatment with Rituximab Combined with Intravenous or Oral Fludarabine for Patients with Extranodal Mucosa Associated Lymphoid Tissue (MALT) Lymphoma.. <i>Blood</i> , 2008 , 112, 2007-2007	2.2
14	Candidemia in Patients with Hematological Malignancies: The Role of Prophylaxis and the Importance of Local Epidemiology for Treatment. <i>Blood</i> , 2008 , 112, 4839-4839	2.2

- 13 Reactivation of Cured Hepatitis B Virus after Allogeneic Hematopoietic Stem Cell Transplantation and Its Association with Liver Graft Versus Host Disease.. *Blood*, **2008**, 112, 2197-2197 2.2
- 12 Therapeutic Compliance and Efficacy of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment of Low Risk Diffuse Large B-Cell Lymphoma Patients: Preliminary Results of An Open-Label Clinical Trial in Spain. *Blood*, **2008**, 112, 4943-4943 2.2
- 11 Identification of Molecular Risk Score in Advanced Hodgkin Lymphoma: Integrating Tumor and Microenvironment Signatures.. *Blood*, **2009**, 114, 3660-3660 2.2
- 10 Efficacy and Safety of Liposomal Cytarabine as Intrathecal Prophylaxis in Patients with Diffuse Large B Cell Lymphoma at High Risk of CNS Involvement: A Multicentric Study Including 80 Patients in Spain.. *Blood*, **2009**, 114, 1663-1663 2.2
- 9 Fecal Calprotectin In Allogeneic Stem Cell Trasplantation as Surrogate Marker of Gastrointestinal Graft Versus Host Disease. *Blood*, **2010**, 116, 2327-2327 2.2
- 8 Mirna EXPRESSION SIGNATURES as PROGNOSTIC Markers IN ADVANCED Classical HODGKIN LYMPHOMA. *Blood*, **2010**, 116, 4157-4157 2.2
- 7 Haemostasis Assessed by Rotational Thromboelastometry and Thrombin Generation Test in Behcet's Disease Patients,. *Blood*, **2011**, 118, 3313-3313 2.2
- 6 Platelet Functions and Risk Prognosis in Myelodysplastic Syndromes,. *Blood*, **2011**, 118, 3806-3806 2.2
- 5 Treatment of Primary Immune Thrombocytopenia with Thrombopoietin Receptor Agonists: Effect On Platelet Function and Plasma Thrombin Generation. *Blood*, **2012**, 120, 1089-1089 2.2
- 4 Thrombopoietin Receptor Agonist (ELTROMBOPAG) for Chronic Immune Thrombocytopenic Purpura (ITP) Treatment: 21 Patients in Only One Center. *Blood*, **2012**, 120, 4658-4658 2.2
- 3 Microparticle-Associated Thrombogenic Mechanism Might Compensate Bleeding Tendency in Patients with Myelodysplastic Syndromes.. *Blood*, **2012**, 120, 2821-2821 2.2
- 2 Effects Of Thrombopoietin Receptor Agonists On APRIL Plasma Levels In Patients With Immune Thrombocytopenia. *Blood*, **2013**, 122, 1083-1083 2.2
- 1 Lenalidomide In Combination With R-ESHAP (LR-ESHAP) In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Candidates To Autologous Stem-Cell Transplantation: A Phase 1b Study From Spanish Group Geltamo. *Blood*, **2013**, 122, 4391-4391 2.2